ZA202309517B - Solid forms of a modulator of hemoglobin - Google Patents

Solid forms of a modulator of hemoglobin

Info

Publication number
ZA202309517B
ZA202309517B ZA2023/09517A ZA202309517A ZA202309517B ZA 202309517 B ZA202309517 B ZA 202309517B ZA 2023/09517 A ZA2023/09517 A ZA 2023/09517A ZA 202309517 A ZA202309517 A ZA 202309517A ZA 202309517 B ZA202309517 B ZA 202309517B
Authority
ZA
South Africa
Prior art keywords
hemoglobin
modulator
solid forms
forms
compound
Prior art date
Application number
ZA2023/09517A
Other languages
English (en)
Inventor
Stephan D Parent
Travis Lee Houston
Courtney S Johnson
Fang Wang
Original Assignee
Global Blood Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Global Blood Therapeutics Inc filed Critical Global Blood Therapeutics Inc
Publication of ZA202309517B publication Critical patent/ZA202309517B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA2023/09517A 2021-05-14 2023-10-11 Solid forms of a modulator of hemoglobin ZA202309517B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163188833P 2021-05-14 2021-05-14
PCT/US2022/029289 WO2022241278A1 (en) 2021-05-14 2022-05-13 Solid forms of a modulator of hemoglobin

Publications (1)

Publication Number Publication Date
ZA202309517B true ZA202309517B (en) 2024-06-26

Family

ID=82020064

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2023/09517A ZA202309517B (en) 2021-05-14 2023-10-11 Solid forms of a modulator of hemoglobin

Country Status (13)

Country Link
US (2) US11851424B2 (cg-RX-API-DMAC7.html)
EP (1) EP4337659A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024520897A (cg-RX-API-DMAC7.html)
KR (1) KR102968809B1 (cg-RX-API-DMAC7.html)
CN (1) CN117337285A (cg-RX-API-DMAC7.html)
AR (1) AR126649A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022273787B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023021606A2 (cg-RX-API-DMAC7.html)
CA (1) CA3219786A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023012156A (cg-RX-API-DMAC7.html)
TW (1) TW202311254A (cg-RX-API-DMAC7.html)
WO (1) WO2022241278A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202309517B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024007064A (es) * 2021-12-10 2024-06-20 Global Blood Therapeutics Inc Metodos de administracion de un modulador de hemoglobina.
EP4727555A1 (en) * 2023-06-13 2026-04-22 Global Blood Therapeutics, Inc. (s)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyd for use in the treatment of sickle cell disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4432987A (en) * 1982-04-23 1984-02-21 Pfizer Inc. Crystalline benzenesulfonate salts of sultamicillin
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
JP6426694B2 (ja) * 2013-03-15 2018-11-21 グローバル ブラッド セラピューティクス インコーポレイテッド ヘモグロビンの修飾のための化合物及びその使用
PT3880654T (pt) * 2018-11-19 2022-04-08 Global Blood Therapeutics Inc Compostos de 2-formil-3-hidroxifeniloximetil capazes de modular hemoglobina
AR126648A1 (es) * 2021-05-14 2023-11-01 Global Blood Therapeutics Inc Métodos para hacer un modulador de hemoglobina
MX2024007064A (es) * 2021-12-10 2024-06-20 Global Blood Therapeutics Inc Metodos de administracion de un modulador de hemoglobina.

Also Published As

Publication number Publication date
JP2024520897A (ja) 2024-05-27
AR126649A1 (es) 2023-11-01
TW202311254A (zh) 2023-03-16
KR20240008356A (ko) 2024-01-18
WO2022241278A1 (en) 2022-11-17
MX2023012156A (es) 2023-10-26
CA3219786A1 (en) 2022-11-17
AU2022273787A1 (en) 2023-10-26
US11851424B2 (en) 2023-12-26
US12473277B2 (en) 2025-11-18
EP4337659A1 (en) 2024-03-20
CN117337285A (zh) 2024-01-02
US20220363674A1 (en) 2022-11-17
KR102968809B1 (ko) 2026-05-26
AU2022273787B2 (en) 2025-04-03
US20240076290A1 (en) 2024-03-07
BR112023021606A2 (pt) 2023-12-19

Similar Documents

Publication Publication Date Title
HUE069590T2 (hu) PCSK9-gátló 6'-[[(1s,3s)-3-[[5-(difluormetoxi)-2-pirimidinil]amino]ciklopentil]amino][1(2h ),3'-bipiridin]-2-on és alkalmazására szolgáló eljárások
MX2021012290A (es) Compuestos de diazina-amida activos como pesticidas.
ZA202107668B (en) Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
MX2021011771A (es) Compuestos de diazina-amida activos como pesticidas.
SA515360022B1 (ar) أملاح وصور صلبة من المركب (s) ــ 3 ــ(4 ــ((4ــ(مورفولينو ميثيل)بنزيل)أوكسي)-1-أوكسو أيزو إندولين-2-يل)ببريدين-2 ،6-دايون، وتركيبات تشتمل عليها، وطرق استخدامها
EP4467143A3 (en) 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile as antiproliferative compound
UA85686C2 (ru) Метансульфонат этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}- 1-метил-1h-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты и его применение как лекарственного средства, способ его получения
IL278854A (en) Treatment of multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(6,2-dioxopyridin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazine-1 -yl-3-fluorobenzonitrile
TW200606144A (en) Crystal of 1,2-dihydropyridine compound
UA88767C2 (uk) Ppar активні сполуки
DK2044043T4 (da) 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazinhydrobromid som en forbindelse med kombineret serotoningenoptag, 5-ht3 og 5-ht1a-aktivitet til behandling af kognitiv svækkelse
GEP20084341B (en) Aminoheteroaryl compounds as protein kinase inhibitors
EP3735243A4 (en) ISOTOPOLOGISTS OF 2- (4-CHLOROPHENYL) -N - ((2- (2,6-DIOXOPIPERIDIN-3-YL) -1-OXOISOINDOLIN-5-YL) METHYL) -2,2-DIFLUOROACETAMIDE
YU91002A (sh) Derivati acilfenil-karbamida, postupak za njihovu proizvodnju i njihova primena kao leka
CL2025000614A1 (es) Moduladores de la alfa-1 antitripsina
IL292265A (en) Methods for treating chronic lymphocytic leukemia using 2-(2,6 deoxypyridin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl(benzyl(amino(amino(isoindoline-1. 3- discussion
BR112022007417A2 (pt) Métodos de tratamento de malignidades hematológicas usando 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil) amino)isoindolina-1,3-diona
GB2615722B (en) Method for cryopreserving engineered tregs
EP4054578A4 (en) COMBINATION THERAPY WITH 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDINE-3-YL)-1-OXOISOINDOLINE-5-YL) METHYL)-2,2-DIFLUOROACETAMIDE
WO2008011483A3 (en) Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds
BR112023021606A2 (pt) Formas sólidas de modulador de hemoglobina
MX2023001805A (es) Formas solidas de 2-(5-(4-(2-morfolinoetoxi)fenil)piridin-2-il)-n- bencilacetamida.
PH12021550432A1 (en) Kits and methods for treating cancers
MX2025004545A (es) 3,4 a, 5, 7, 8, 8a-hexahidro-4h-tiopirano [4,3-d] pirimidin-4-onas 2-sustituidas para el tratamiento de heridas
DK1518857T3 (da) Fremgangsmåde til fremstilling af pantoprazol og salte deraf